6ML.F MOLECULAR PARTNERS SF 1
- Market cap
- EUR 106M
- P/E
- -
- P/B
- 1.87x
- ROE
- -101.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6ML.F undervalued?
Graham numberThe Graham number of MOLECULAR PARTNERS SF 1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MOLECULAR PARTNERS SF 1 fundamental analysis
No fundamental analysis for MOLECULAR PARTNERS SF 1 yet.
MOLECULAR PARTNERS SF 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MOLECULAR PARTNERS SF 1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) …
Full company profileMOLECULAR PARTNERS SF 1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MOLECULAR PARTNERS SF 1 annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 9.33M | 190M | 7.04M | 4.97M | 0.00 | 0.00 |
| Operating Income | -63.4M | 117M | -61.1M | -61.2M | -55.4M | -52.1M |
| EBITDA | - | 121M | -59.5M | -51.6M | -59.5M | -49.2M |
| Net Income | -63.8M | 118M | -62.0M | -54.0M | -61.7M | -51.2M |
| EPS | -1.98 | 3.27 | -1.89 | -1.47 | -1.65 | -1.34 |
| Balance Sheet | ||||||
| Total Assets | 173M | 262M | 198M | 159M | 102M | 64.5M |
| Total Liabilities | 65.4M | 27.1M | 21.9M | 16.9M | 21.8M | 13.9M |
| Shareholders' Equity | 107M | 235M | 176M | 142M | 80.3M | 50.7M |
| Cash & Short-term Investments | 71.8M | 87.9M | 67.3M | 63.9M | 82.7M | 57.5M |
| Cash Flow | ||||||
| Operating Cash Flow | -91.0M | 119M | -59.0M | -59.2M | -51.3M | -47.4M |
| Capital Expenditure | 1.31M | 1.42M | 808K | 723K | 714K | 0.00 |
| Free Cash Flow | -92.3M | 117M | -59.8M | -60.0M | -52.0M | -47.4M |
| Ratios | ||||||
| ROE | -59.5% | 50.1% | -35.1% | -38.2% | -76.7% | -101.1% |
| ROA | -36.9% | 44.9% | -31.2% | -34.1% | -60.4% | -79.4% |
| Net Profit Margin | -683.7% | 62.2% | -880.7% | -1,087.4% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MOLECULAR PARTNERS SF 1 dividends
MOLECULAR PARTNERS SF 1 has not paid dividends in the last 5 fiscal years.
Who owns MOLECULAR PARTNERS SF 1
- Insiders 8.47%
- Institutions 43.78%
- Public & others 47.76%
- Shares outstanding 38.3M
- Free float 20.7M
MOLECULAR PARTNERS SF 1 company profile
- Company name
- MOLECULAR PARTNERS SF 1
- Ticker
- 6ML.F
- ISIN
- CH0256379097
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 134
- Fiscal year end
- December
- Address
- Wagistrasse 14, Schlieren, Switzerland, 8952
- Phone
- 41 44 755 77 00
- Website
- molecularpartners.com
About MOLECULAR PARTNERS SF 1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
MOLECULAR PARTNERS SF 1 management
10- Dr. Patrick Amstutz Ph.D.Co-Founder, CEO, Member of Management Board & Director · born 1975
- Dr. Michael Tobias Stumpp Ph.D.Co-Founder, Executive VP of Projects & Member of Management Board · born 1972
- Mr. Robert HendriksSenior VP of Finance & Member of Management Board
- Mr. Alexander ZurcherCOO & Member of Management Board · born 1975
- Ms. Renate GloggnerExecutive VP of People & Community and Member of Management Board · born 1970
- Dr. Philippe Legenne M.B.A., M.D.Chief Medical Officer & Member of the Management Board · born 1966
- Mr. Martin Steegmaier Ph.D.Chief Scientific Officer & Member of the Management Board · born 1966
- Mr. Michael PitznerExecutive VP of Partnering & General Counsel
- Dr. Pamela A. Trail Ph.D.Strategic Consultant · born 1956
- Mr. Daniel Steiner Ph.D.Senior Vice President of Targeted Radio Therapeutics